Folic Acid
| Evidence Level: L4 | Predicted Indications: 1 |
Table of Contents
- Folic Acid
- Pharmacist Assessment Report
- Folic Acid: From Folate-Deficiency and Other Anaemias to Biotin Metabolic Disease
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Folic Acid: From Folate-Deficiency and Other Anaemias to Biotin Metabolic Disease
One-Sentence Summary
Folic acid is a B-vitamin originally used to treat vitamin deficiency disorders and anaemias, including folic acid deficiency anaemia and iron deficiency anaemia. The TxGNN model predicts it may be effective for biotin metabolic disease, but there are currently no registered clinical trials and only review-level literature (about 20 publications, none showing a direct folic acid effect) behind this prediction. The high score most likely reflects network proximity between B-vitamins rather than a true therapeutic effect.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Vitamin deficiency disorder; folic acid deficiency anaemia; iron deficiency anaemia (the ARTG entry in the compiled data has no approved indication text) |
| Predicted New Indication | Biotin metabolic disease |
| TxGNN Prediction Score | 0.9949 |
| Evidence Level | L4 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available for this drug. Folic acid is a B-vitamin that serves as a cofactor in one-carbon metabolism, and its efficacy in folate-deficiency anaemia is well established.
Folate and biotin are both B-vitamin cofactors, and the literature groups them together as “vitamin-responsive disorders”. This shared grouping is probably what drives the high TxGNN score.
However, the mechanistic link is weak. Folic acid does not replace biotin function. Biotinidase deficiency and holocarboxylase synthetase deficiency are treated with biotin itself. The prediction should be read as a computational association among vitamins, not as evidence of a direct therapeutic effect.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
The retrieved literature is mainly narrative reviews of vitamins and metabolic disease. None of it tests folic acid in biotin metabolic disease.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23622402 | 2013 | Review | Handbook of Clinical Neurology | Vitamin-responsive disorders (cobalamin, folate, biotin, B1, E); describes inborn errors of vitamin absorption, transport and metabolism |
| 7027768 | 1981 | Review | Acta Vitaminologica et Enzymologica | Vitamins in metabolic diseases; some vitamin-dependent syndromes need pharmacological doses of the specific vitamin |
| 38203763 | 2024 | Review | Int J Mol Sci | Vitamin B12 deficiency and the nervous system; notes the links among B12, biotin and folate in metabolic reactions |
| 37123774 | 2023 | Review | Cureus | Vitamins and type 2 diabetes; thiamine, pyridoxine and biotin levels are lower in people with diabetes |
| 25388747 | 2015 | Review | Endocr Metab Immune Disord Drug Targets | Vitamins and type 2 diabetes; reports low B-group vitamin levels |
| 41692080 | 2026 | Review | Clinics in Dermatology | B vitamins in dermatology; roles in cellular metabolism and red cell synthesis |
| 39828265 | 2025 | Umbrella review | Asia Pac J Clin Nutr | Water-soluble vitamins and glycaemic control in type 2 diabetes; prior meta-analyses were inconsistent |
| 14989256 | 2004 | Narrative article | Arch Biochem Biophys | Micronutrient deficiencies (including folic acid and B12) may damage DNA; argues for optimised intake |
| 16183151 | 2006 | Preclinical (rat) | Int J Cardiol | Folic acid reduced VCAM-1 expression in the aorta of rats with hyperhomocysteinaemia; not related to biotin |
| 13199008 | 1954 | Animal study | Biologica Latina | Biotin and combined biotin and folic acid deficiency induced in rats; a deficiency model, not a treatment study |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 10573L | Megafol 5 | Tablet 5 mg (oral) | Not available in the compiled data |
Safety Considerations
- Drug Interactions: 100 interactions were identified in total. The main graded ones are pancrelipase (Moderate) and sulfasalazine (Minor). Many others are listed with unknown severity, including metformin, omeprazole, pantoprazole, lansoprazole, glimepiride, acarbose, rosiglitazone, simvastatin, prednisone, triamcinolone, mesalazine, sucralfate, vancomycin, morphine, lactulose, nizatidine, palonosetron and calcitriol.
Please refer to the TGA-approved Product Information (PI) for label warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on no clinical trials and only indirect review literature. Biotin metabolic disorders are treated with biotin itself, and folic acid has no known role in correcting the defect. The high TxGNN score likely reflects similarity among vitamins rather than a therapeutic effect.
To proceed, the following is needed:
- Mechanism of action data and a clear biological rationale for folic acid in biotin metabolism
- Preclinical or clinical studies that test folic acid, not biotin, in biotinidase or holocarboxylase synthetase deficiency
- Retrieval of the TGA-approved Product Information (PI), including approved indications, warnings and contraindications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.